Canada Drug Agency Recommends Public Reimbursement of Biogen’s LEQEMBI
Canada’s Drug Agency (CDA-AMC) issued a final recommendation supporting public reimbursement of LEQEMBI for eligible patients in Canada with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The therapy’s dosing has been approved in multiple countries, with further submissions underway, while a Phase 3 study in preclinical AD remains ongoing since 2020.
Coverage (4)
- Eisai and Biogen Announce Canada’s Drug Agency Final Recommendation Supporting Public Reimbursement of LEQEMBI for Eligible Early Alzheimer’s Disease Patients (quiverquant.com)
- Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease (investors.biogen.com)
- Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease (globenewswire.com)
- Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease (globenewswire.com)